Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) generates frequent news as a clinical-stage biotechnology company advancing regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense programs. News coverage on this page centers on the company’s clinical data, regulatory designations, intellectual property developments, and strategic initiatives built around its AlloStem, ImmCelz, and iPScelz platforms.
Readers can follow detailed updates on CELZ-201 (olastrocel), the company’s lead allogeneic perinatal tissue–derived cell therapy. Recent announcements include interim 180-day results from the FDA-cleared ADAPT trial in chronic lower back pain associated with degenerative disc disease, showing statistically significant and clinically meaningful improvements in functional disability and pain with a favorable safety profile. Additional news highlights FDA Fast Track designation for CELZ-201-DDT and progress in the CREATE-1 trial for new-onset Type 1 diabetes.
CELZ news also covers the company’s BioDefense Inc. subsidiary and its Burn Pit Initiative, which has received regulatory approval to proceed. Articles describe plans to build a large molecular and cellular database for veterans exposed to toxic burn pits, supported by AI-driven molecular modeling and regenerative countermeasure development using the iPScelz platform and collaborations with partners such as Greenstone Biosciences.
Investors can review press releases on patent allowances and issued patents for ImmCelz-based regenerative immunotherapy in Type 1 diabetes and heart failure, as well as corporate communications such as shareholder letters outlining platform strategy, AI integration, and clinical milestones. Capital markets updates, including warrant exercise agreements and related proxy materials, are also reflected in the news flow.
For anyone tracking CELZ, this news feed provides a centralized view of clinical trial milestones, regulatory events, biodefense initiatives, and financing disclosures that shape the company’s development as a clinical-stage biotechnology issuer.
Creative Medical Technology Holdings (OTC: CELZ) plans to launch Virtual Physician™, a telehealth platform for regenerative medicine, this summer. The platform aims to educate, recruit, and retain patients for their proprietary procedures, such as CaverStem® for erectile dysfunction and FemCelz® for vaginal rejuvenation. As additional products like StemSpine® are commercialized, the platform will expand. The initiative is expected to create shareholder value through a Management Service Organization model, royalties from product promotions, and direct sales of ancillary products.
Creative Medical Technology Holdings (OTC: CELZ) announced the FDA issued IND Number 27375 for its clinical trial using ImmCelz® to treat stroke victims. ImmCelz® utilizes stem cells to reprogram immune cells, enhancing their regenerative capabilities. This milestone is seen as a significant step for the company as it moves toward clinical application. Timothy Warbington, President and CEO, expressed optimism about progressing with the FDA. The company specializes in regenerative medicine across various fields including immunotherapy and neurology.
Creative Medical Technology Holdings (OTC: CELZ) has initiated the recruitment of clinical sites for its StemSpine® procedure, aimed at treating Degenerative Disc Disease (DDD). This patented regenerative stem cell procedure has shown significant efficacy, reporting an 85% reduction in pain over 12 months from a baseline of 8.9. The company plans to geographically disperse sites across the USA to maximize patient access. The first 100 patients will be monitored at intervals of 30 days, 6 months, and 12 months, with results set for publication in a peer-reviewed journal.
Creative Medical Technology Holdings (OTC - CELZ) announced a significant publication on its clinical trial involving stem cell therapy for patients with disc degenerative disease. The study showed a mean pain score reduction from 8.9 at baseline to 1.3 at 12 months, with a noted decrease in pain medication use. The procedure was reported to have no serious adverse effects. The company is poised to commercialize this therapy, expanding its market in the multi-billion dollar industry.
Creative Medical Technology Holdings (OTC-CELZ) announced its plan to resubmit the ImmCelz® Investigational New Drug Application (IND) to the FDA due to COVID-related changes in submission requirements. The resubmission will be in electronic format to comply with the new regulations. The company has engaged an FDA consulting firm to assist with the electronic submission process. The resubmission will not alter the substance of the original application, which aims to initiate clinical trials on cellular immunotherapy for stroke treatment.
Creative Medical Technology Holdings (OTC – CELZ) announced the filing of a patent application for its ImmCelz® regenerative cell therapy, aimed at preventing organ transplant rejection. ImmCelz® works by stimulating T regulatory cells and producing Hepatocyte Growth Factor (HGF), potentially inhibiting chronic graft rejection, a leading cause of organ loss. The company has observed therapeutic effects of ImmCelz® in various conditions, including rheumatoid arthritis and kidney failure, and aims to expand its intellectual property portfolio in regenerative medicine.
On February 10, 2021, Creative Medical Technology Holdings (OTC-CELZ) revealed new data on its patented OvaStem® treatment for female infertility and ovarian failure. This treatment involves injecting stem cells to restore hormone levels and induce fertility, supported by patent #10,792,310. Recent findings show that mesenchymal stem cell injections generate T regulatory cells, enhancing ovarian function. The company aims to file for FDA clinical trials, focusing initially on premature ovarian failure, a condition affecting women under 40. The menopause market is estimated at $600 billion, highlighting significant potential.
Creative Medical Technology Holdings (OTC-CELZ) has appointed Dr. Caigan Du, an Associate Professor at the University of British Columbia, to its Scientific Advisory Board. Dr. Du is recognized for his research on kidney failure and transplant rejection, and has received funding from key organizations. He expressed enthusiasm about the potential of ImmCelz®, a regenerative therapy utilizing reprogrammed immune cells to aid kidney regeneration. This recruitment aims to enhance the company's scientific leadership in regenerative medicine.
Creative Medical Technology Holdings, Inc. (OTC – CELZ) announced promising data on ImmCelz®, revealing that its administration significantly increases hepatocyte growth factor (HGF-1) in treated animals. This study indicates that the therapeutic effects of ImmCelz® are contingent upon HGF-1. The company has previously identified therapeutic activity in various diseases, including rheumatoid arthritis and stroke. The CEO emphasized the importance of understanding biological mechanisms for attracting investments in regenerative immunotherapy, leading to new patent applications based on these findings.
Creative Medical Technology Holdings (CELZ) announced promising proof of concept studies for its ImmCelz® immunotherapy in a collagen-induced rheumatoid arthritis model. The studies highlighted that ImmCelz® effectively suppresses harmful autoimmunity without compromising normal immune functions, potentially reducing treatment-related infection risks. CEO Timothy Warbington noted the potential for rapid clinical application of these findings. ImmCelz® utilizes reprogrammed immune cells derived from adult stem cells, aiming at a significant multi-billion dollar market for autoimmune conditions.
FAQ
What is the current stock price of Creative Med Technology Hldgs (CELZ)?
What is the market cap of Creative Med Technology Hldgs (CELZ)?
